Robert Jeng

Just me.

[Robert Jeng @robert_jeng]

Great crowd marching in san marcos. #NeverTrump

[David Dahan, PhD @BMT_David1]

Results from Lonca-T, an anti CD19 ADC in r/r DLBCL

[Zachary McLellan @biotechzm]

#ASH17 Acalabrutinib data from the ACE-LY-004 study in Mantle Cell Lymphoma.

[David Dahan, PhD @BMT_David1]

Acalabrutinib was approved for relapsed MCL #ASH2017

[Zachary McLellan @biotechzm]

#ASH17 begins. Follow along for tweets and updates.

[David Dahan, PhD @BMT_David1]

MAbtyrin, a Multivalent anti S. aureus biological #IDWeek2017

[Robert Jeng @robert_jeng]

$IPCI abuse-deterrent oxycodone formulation, Rexista, receives CRL. https://t.co/aNIOqwhwjf

[Robert Jeng @robert_jeng]

Allergan receives Refusal to File from FDA for Vraylar for negative symptoms of schiz.

[Amanda Micklus @amandamicklus]

7th #biosimilar approved in US, first in #oncology indication, first referencing Avastin $AMGN/ $AGN Mvasi https://t.co/2zfEGyDhaX

[Mandy Jackson @ScripMandy]

Great read on $AGN's role, for better or worse, as a #pharma industry leader. https://t.co/2pJhfleTyn

[Amanda Micklus @amandamicklus]

$GILD was going to do a big deal sooner than later, but surprised it's in CAR-T $KITE https://t.co/9DRC5qczS4

[Kevin Shannon @kj_shannon15]

$NVO Victoza receives first label addition for reduced risk of all MACE in T2DM, gives an edge over Trulicity https://t.co/wz1WPcfgYf $LLY

[Jack Allen @JohnK_Allen]

$KITE relays that FDA will not require an ad-com for axi-cel, likely signaling quick approval, attention to now turn to payers

$JUNO $NVS

[Robert Jeng @robert_jeng]

Sirukumab fails FDA adcomm with final 1Y:11N vote on approval. $JNJ

[Robert Jeng @robert_jeng]

Imbruvica (ibrutinib) approved for GvHD. $ABBV https://t.co/r5w1ykFahz

[Robert Jeng @robert_jeng]

Opdivo (nivolumab) receives FDA conditional approval for MSI-H or dMMR colorectal cancer. $BMY
https://t.co/X0owJEPlYQ

[Kevin Shannon @kj_shannon15]

Opdivo beat sales consensus by 4% 1.195bn vs 1.146bn https://t.co/EQQGUiFowQ

[Peter Chang @PChangMD1]

$MRK anacetrapib REVEAL had enough primary events, that could meet p of 0.05 with only a 9% reduction(# planned primary events < IMPROVE-IT)

[David Dahan, PhD @BMT_David1]

Trial starting soon, CD19-28-Z CAR co-expressed with 41BB+ligand

[David Dahan, PhD @BMT_David1]

Checkpoint inhibitors in AML, Opdivo + azacitidine combo #eha2017